Nina Schäfer and Jin Ito contributed to this article. On November 25, 2020, the European Commission (the “Commission”) published its “Pharmaceutical Strategy fo

Researchers around the world are working at record speed to find the best ways to treat and prevent COVID-19. In this last episode of our four-part podcast seri

MoFo & GSAS Harvard Biotech Club’s new course, “Legal Topics for Scientists, Entrepreneurs, and Start Ups,” started on November 11, with more than 100 life scie

The GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups features a combination of lectures and

In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine. Mic

In this second of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security considerations of each

In this first of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security considerations of each

“What can be a better day to talk about the complex CRISPR/Cas9 patent landscape than the big day that the Nobel Prize was awarded to pioneers of this revolutio

In this third installment of a six-part Patent Law Course offered by Morrison & Foerster and GSAS Harvard Biotech Club, MoFo partner and head of the firm’s Chin

Morrison & Foerster LLP partner, founder and head of MoFo’s antibody IP practice James Mullen taught a class in patent drafting to members of the GSAS Harvard B